In vitro generation of dendritic cells by exposure to an anti-CSF1-R antibody
US9676859B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Nov 8, 2013 |
| Grant date | Jun 13, 2017 |
| Priority date | — |
| Expiry date | Nov 8, 2033 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2501/22
- WIPO fieldBiotechnology
- WIPO sectorChemistry
Abstract
The invention is generally directed to promoting dendritic cells (DCs), and optionally M1-type (macrophage M1 polarization), immune response by administering a compound that modulates macrophage polarization. The invention is directed to the use of an antibody able to bind to CSF-1R for modulating macrophage polarization. The invention is also directed to methods for evaluating the dose efficacy of an antibody able to bind to CSF-1R in a patient by assessing the in vivo or in vitro polarization of macrophages. The invention is further directed to post-treatment companion test and assays to assess the effect of an antibody able to bind to CSF-1R on a subject being treated.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.